State of Michigan Retirement System Purchases 280,900 Shares of Hims & Hers Health, Inc. $HIMS

State of Michigan Retirement System raised its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 13.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,338,600 shares of the company’s stock after buying an additional 280,900 shares during the period. State of Michigan Retirement System’s holdings in Hims & Hers Health were worth $48,549,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its position in Hims & Hers Health by 7.2% during the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after acquiring an additional 1,407,651 shares during the last quarter. Farallon Capital Management LLC raised its position in Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the last quarter. State Street Corp grew its holdings in shares of Hims & Hers Health by 1.8% during the fourth quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after purchasing an additional 132,311 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Hims & Hers Health by 12.4% during the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after purchasing an additional 608,950 shares during the last quarter. Finally, Invesco Ltd. increased its stake in shares of Hims & Hers Health by 62.7% in the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after buying an additional 1,600,004 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Insider Activity at Hims & Hers Health

In other news, COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total value of $441,850.50. Following the transaction, the chief operating officer directly owned 432,124 shares in the company, valued at $13,611,906. This trade represents a 3.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David B. Wells acquired 48,400 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were bought at an average cost of $24.23 per share, with a total value of $1,172,732.00. Following the completion of the purchase, the director owned 224,417 shares of the company’s stock, valued at $5,437,623.91. This trade represents a 27.50% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have sold 167,161 shares of company stock worth $5,041,152. 11.76% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of research analyst reports. Wall Street Zen cut Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Bank of America raised their price objective on shares of Hims & Hers Health from $36.00 to $37.00 and gave the company a “neutral” rating in a research report on Thursday, July 9th. Needham & Company LLC raised their price objective on shares of Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Barclays boosted their target price on shares of Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 17th. Finally, Jefferies Financial Group set a $24.50 target price on shares of Hims & Hers Health in a research report on Tuesday, May 12th. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $30.70.

Hims & Hers Health Trading Up 0.0%

HIMS stock opened at $34.40 on Tuesday. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $70.43. The company has a market cap of $7.96 billion, a P/E ratio of -382.19, a PEG ratio of 96.75 and a beta of 2.35. The business has a fifty day moving average of $29.51 and a 200-day moving average of $26.33.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The business had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. During the same period last year, the business posted $0.20 EPS. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.03 EPS for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.